Research. Advocacy. Support.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing recurrent ovarian cancer, discussing the goals of treatment during recurrence, typical courses of treatment, and advice on how to approach making decisions about treatment during… More
OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants. Ronald Alvarez, MD, MBA, of Vanderbilt University Medical Center, Deborah Armstrong, MD, of Johns Hopkins School of Medicine, Robert Coleman, MD, of M.D. Anderson Cancer… More
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated. Senescence can be very useful, for example, when one wants to stop cancer cells from rapidly dividing, but there can be negative side… More
A Taste of our 12TH Annual Gala! Masters of Ceremonies Tommy McFly, Kelly Collis & Jen Richer&nd...February 22, 2017 @ 6:00 pm - 9:00 pm EST
At the 2016 Ovarian Cancer National Conference, attendees heard from the country’s top researc...July 7, 2017 @ 8:00 am - July 9, 2017 @ 5:00 pm EDT
OCRFA’s Super Saturday is a daylong shopping event that brings top luxury name brands in high ...July 29, 2017 @ 8:00 am - 5:00 pm EDT